千金药业: 湖南启元律师事务所关于株洲千金药业股份有限公司2021年限制性股票激励计划回购注销部分限制性股票实施情况的法律意见书

Core Viewpoint - The legal opinion letter from Hunan Qiyuan Law Firm confirms that Zhuzhou Qianjin Pharmaceutical Co., Ltd. has obtained the necessary approvals and authorizations for the repurchase and cancellation of certain restricted stocks under its 2021 incentive plan, in compliance with relevant laws and regulations [2][11][14] Group 1: Approval and Authorization - The company has completed the necessary procedures for the repurchase and cancellation of restricted stocks as part of its incentive plan [4][11] - The independent directors have expressed their agreement with the relevant proposals regarding the incentive plan [5][9] - The company has received approval from the Zhuzhou Municipal Government's State-owned Assets Supervision and Administration Commission for the implementation of the incentive plan [6][11] Group 2: Repurchase and Cancellation Details - The repurchase and cancellation are due to the failure to meet performance assessment requirements, specifically a revenue growth rate of at least 50% for the second release period and 75% for the third release period compared to 2020 [11][12][13] - A total of 5,490,000 shares will be repurchased and canceled, involving 121 individuals [12][13][14] - The repurchase is expected to be completed by July 10, 2025, with necessary filings to be made with the relevant authorities [13][14] Group 3: Compliance and Legal Opinion - The legal opinion asserts that the reasons, quantities, and arrangements for the repurchase and cancellation comply with the relevant management measures and regulations [11][14] - The company is required to fulfill its information disclosure obligations and handle the reduction of registered capital [14]